Background {#Sec1}
==========

Pulmonary morbidity is a key issue in the treatment of premature infants. In the first postnatal days, respiratory distress syndrome (RDS) is, next to early-onset infection, one of the most important and common diseases affecting the lung.

Recent evidence suggests that RDS is best treated by continuous positive airway pressure (CPAP) combined with less invasive surfactant administration (LISA, \[[@CR1]--[@CR3]\]). Most reports using this approach administered surfactant via a thin catheter (TCA, \[[@CR3]--[@CR6]\]); this was also favored in a recent update of the European Consensus Guidelines on the Management of Respiratory Distress Syndrome \[[@CR4]\].

Although most LISA reports and recently developed LISA catheters, such as LisaCath \[[@CR5]\] or Neofact (formerly QuickSF \[[@CR6]\]) prefer the oral route for insertion, the use of a nasally guided, soft umbilical vein catheter (LISA-n) is quite common in Germany. This involves the theoretical risk of catheter contamination with bacteria residing in the upper respiratory tract. It is unclear, however, how common this occurs in practice. We thus set out to quantify this risk in infants with RDS treated via LISA-n.

Main objective of this study was to evaluate microbiological contamination of the catheters used in LISA-n procedures and its association with postnatal age.

Methods {#Sec2}
=======

Ethical conditions {#Sec3}
------------------

The study protocol was approved by the Ethics committee of University Hospital Tübingen. Samples were cultured anonymously (only numbered by order of occurrence). Parents gave written consent to their baby's study participation.

Collection of samples {#Sec4}
---------------------

We planned to collect 20 catheter tips from infants with RDS (gestational age, 23 + 0/7--36 + 0/7 weeks) and a clinical indication of surfactant administration following the LISA-n procedure. Catheters used were umbilical vein catheters with a diameter of 2.5 to 3.5 French. Following surfactant administration, catheters were removed and the tip (\~ 1-3 cm) was cut with sterile scissors and directly placed in a sterile eSwab container with 1 ml liquid Amies solution (Copan Diagnostics, Murrieta, CA). After that, they were sent anonymously (only labelled with the study title and the next consecutive number) to the microbiology laboratory for culture; this happened immediately after the procedure if occurring on weekdays between 8 am and 8 pm, or following storage in a refrigerator at 4--8 °C till the next morning. Room temperature was allowed for no more than 2 h; also, if storage exceeded 24 h, the sample was discarded.

A consignment note to each sample collected the details of the infant's medical history (e.g. postnatal age at the time of the procedure, number of surfactant administrations, etc.) and remained on the ward. Anonymization of the consignment note took place after reaching 48 h of postnatal age.

Microbiological procedures {#Sec5}
--------------------------

Specimens were thoroughly vortexed and 10 μl of Amies medium diluted in 990 μl sterile sodium chloride solution (0.9%). 100 μl of the undiluted sample and 100 μl of the dilution were then cultured for 48 h at 36 ± 1 °C on the following solid media: Columbia sheep blood agar (Oxoid, Thermo Fisher Diagnostics, Wesel, Germany) and Endo agar supplemented with 1% fuchsine (Oxoid) under aerobic conditions, plus brain heart infusion agar (Oxoid) with 5% sheep blood and IsoVitaleX enrichment (BD, Sparks, MD) under anaerobic conditions. Agar dishes were checked for microbial growth after 24 and 48 h.

In case of growth, colony forming units (CFU) were counted and microbes identified based on morphology, hemolysis, catalase and/or DNase production, as well as Staph Plus Latex Kit (DiaMondiaL, Sees, France).

Statistical analysis {#Sec6}
--------------------

All analyses were descriptive and results were grouped by postnatal age: \< 4 h, 4--18 h, \> 18 h.

Results {#Sec7}
=======

25 catheter-tips were collected between September 2018 and June 2019. Infants included into the study had a mean gestational age of 28 weeks (range 24--33 weeks). Baseline characteristics of the included infants, timing of the surfactant administrations, collection of samples and microbiological findings are shown in Table [1](#Tab1){ref-type="table"}. Table 1Baseline characteristics of included infants, timing of surfactant doses, collection of samples and microbiological findingsNo.Gestational age at birth in weeksWeight at birth in gramTime of surfactant administration after birth in hours: minutes\
\*cultured sample; \*e collected, but excluded; ^\--^ missedMicrobiological findings Bacterium (Colony Forming Units (CFU))1st dose2nd dose3rd dose124 + 5/734500:13 ^\--^***09:09 \****--**viridans group streptococci (160 CFU)**233 + 2/71730**34:23 \***----**--**329 + 0/71190**05:30 \***----**--**429 + 6/7160000:22 ^\--^**17:22 \***--**--**525 + 0/766002:10 \*e**17:50 \***--**--**627 + 2/7980**01:02 \***----**--**731 + 4/72145**00:12 \***----**--**828 + 6/71340**01:49 \***----**--**931 + 2/7149000:20 ^\--^**02:38 \***18:53 ^\--^**--**1033 + 1/71990***25:21 \****----**viridans group streptococci (160 CFU) coagulase-negative staphylococci (90 CFU)**1130 + 0/7980***33:58 \****----**coagulase-negative staphylococci (30 CFU)**1230 + 2/71220**00:08 \***----**--**1326 + 6/7655**26:21 \***----**--**1425 + 4/7495**02:24 \***37:09 ^\--^--**--**1525 + 2/7685**00:43 \***----***Staphylococcus aureus*(60 CFU)**1629 + 5/71380**02:56 \***----**--**1724 + 6/7880**01:14 \***16:12 \*e--**--**1825 + 4/755501:03 ^\--^**14:20 \***--**--**1927 + 1/7585**00:27 \***----**--**2030 + 0/778014:21 ^\--^17:55 \*e**21:40 \*--**

LISA-n was performed from 1 to a maximum of 3 times (overall mean: 1.5 times; 1.3 times in positive samples and 1.6 times in negative samples). Mean postnatal age at sample collection was 11.0 h (range: 0.1--34.4 h); it was 9.4 h (range: 0.1--34.4) in those with negative, and 17.3 h (range: 0.7--34.0 h) in those with positive microbiological culture results.

Five catheter tips had to be excluded because storage time had been \> 24 h or they came from an infant already enrolled. Of the remaining 20 catheter tips, 4 showed a positive culture result (20%, see Table [1](#Tab1){ref-type="table"}).

The calculated risk of catheter contamination increased with postnatal age (see Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Risk of positive microbiological findings in the selected time periods

Discussion {#Sec8}
==========

We found a 20% risk of bacterial contamination for nasally introduced catheters, which increased with postnatal age. All bacterial species identified are known to be potentially associated with the development of early onset neonatal sepsis \[[@CR7]\]. We do not know, however, whether our findings would have any effect on clinical outcome. Since differentiation of radiological signs of pneumonia and RDS is difficult and biochemical and clinical signs of sepsis might be affected by other reasons (e.g. prenatal infection that could have caused premature birth) a much higher sample size would be required to assign such findings to the surfactant administration procedure.

Results of this study are limited by the fact that it remains unclear whether the bacteria from positive catheter tips had already colonized the trachea \[[@CR8]\] or whether colonization took place during catheter removal, which would then not involve a risk of transmission. This would have required an additional intratracheal smear before implementation of the LISA-catheter, which was regarded too invasive.

However, colonization of the catheter tip took place during its pathway through the upper respiratory tract (including the trachea) and by this there is a potential risk of microbe transmission when a LISA procedure is performed via the nasal route, as is probably also true for any nasally introduced endotracheal tube. Additionally, the risk of positive microbial culture results increased with postnatal age. This was expected owing to the fact that higher postnatal age will be accompanied with a higher rate of bacterial colonization of the pharynx and gastrointestinal tract.

Surfactant administration occurring immediately after birth is known to achieve a better effect in reducing air leaks than later surfactant administration. It also decreases the risk of pneumothorax, pulmonary interstitial emphysema, neonatal mortality and chronic lung disease in comparison to later rescue surfactant \[[@CR9]\]. Additionally, late surfactant administration may also increase the risk of patent ductus arteriosus \[[@CR10]\]. An increasing risk of bacterial catheter contamination as shown here adds another argument why early identification of infants requiring exogenous surfactant is important.

Conclusion {#Sec9}
==========

It could be hypothesized that there is a potential risk of microbial transmission to the trachea of neonates in LISA-n procedures with higher postnatal age. However, it remains unclear if the findings of this study reflect the risk of transmission or colonization of the trachea. If there is a risk of microbe transmission, it is also unknown if orally guided catheters during LISA or other TCA procedures would minimize this risk. Earlier administration of surfactant after birth would reduce this risk, thus early identification of infants who require surfactant would be important.

Further studies will be needed to determine if these findings have any effect on clinical outcome.
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